Advisor Group Inc. boosted its holdings in Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) by 70.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 43,650 shares of the biopharmaceutical company’s stock after buying an additional 18,025 shares during the quarter. Advisor Group Inc.’s holdings in Synergy Pharmaceuticals were worth $127,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of SGYP. Principal Financial Group Inc. grew its position in Synergy Pharmaceuticals by 12.9% in the first quarter. Principal Financial Group Inc. now owns 37,343 shares of the biopharmaceutical company’s stock worth $174,000 after buying an additional 4,267 shares during the last quarter. Teachers Advisors LLC grew its position in Synergy Pharmaceuticals by 12.9% in the first quarter. Teachers Advisors LLC now owns 337,439 shares of the biopharmaceutical company’s stock worth $1,572,000 after buying an additional 38,658 shares during the last quarter. Legal & General Group Plc grew its position in Synergy Pharmaceuticals by 12.2% in the first quarter. Legal & General Group Plc now owns 49,476 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 5,367 shares during the last quarter. Vanguard Group Inc. grew its position in Synergy Pharmaceuticals by 18.8% in the first quarter. Vanguard Group Inc. now owns 15,785,763 shares of the biopharmaceutical company’s stock worth $73,561,000 after buying an additional 2,493,557 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in Synergy Pharmaceuticals by 12.8% in the first quarter. Geode Capital Management LLC now owns 1,670,188 shares of the biopharmaceutical company’s stock worth $7,782,000 after buying an additional 189,235 shares during the last quarter. Hedge funds and other institutional investors own 60.53% of the company’s stock.

Several research analysts have issued reports on SGYP shares. HC Wainwright restated a “buy” rating and issued a $8.00 price target (down previously from $15.00) on shares of Synergy Pharmaceuticals in a research report on Monday, September 25th. They noted that the move was a valuation call. Cantor Fitzgerald reiterated an “overweight” rating and set a $11.00 price objective on shares of Synergy Pharmaceuticals in a research report on Friday, September 8th. BidaskClub cut shares of Synergy Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 5th. Zacks Investment Research upgraded shares of Synergy Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, September 13th. Finally, Oppenheimer set a $6.00 price objective on shares of Synergy Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, October 10th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $7.93.

In other Synergy Pharmaceuticals news, major shareholder Paulson & Co. Inc. sold 8,750,000 shares of Synergy Pharmaceuticals stock in a transaction on Friday, November 10th. The shares were sold at an average price of $2.82, for a total transaction of $24,675,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 3.80% of the company’s stock.

Synergy Pharmaceuticals, Inc. (SGYP) opened at $2.00 on Friday. Synergy Pharmaceuticals, Inc. has a 52-week low of $1.68 and a 52-week high of $7.15. The company has a debt-to-equity ratio of -68.13, a current ratio of 4.26 and a quick ratio of 3.88.

Synergy Pharmaceuticals (NASDAQ:SGYP) last posted its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.06. The firm had revenue of $5.01 million for the quarter, compared to analysts’ expectations of $4.53 million. During the same quarter in the previous year, the firm posted ($0.22) earnings per share. equities research analysts forecast that Synergy Pharmaceuticals, Inc. will post -1.07 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Advisor Group Inc. Acquires 18,025 Shares of Synergy Pharmaceuticals, Inc. (SGYP)” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/advisor-group-inc-acquires-18025-shares-of-synergy-pharmaceuticals-inc-sgyp/1738717.html.

Synergy Pharmaceuticals Profile

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Want to see what other hedge funds are holding SGYP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP).

Institutional Ownership by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.